Valuation: Verastem, Inc.

Market Cap 530M 464M 429M 395M 745M 51.1B 757M 5.13B 2.01B 25B 1.99B 1.95B 86.14B P/E 2026 *
-3.81x
P/E 2027 * -5.38x
Enterprise Value 365M 320M 296M 272M 513M 35.19B 521M 3.53B 1.39B 17.22B 1.37B 1.34B 59.31B EV / Sales 2026 *
3.58x
EV / Sales 2027 * 1.8x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-4.23%
1 week+7.08%
Current month+50.52%
1 month+35.29%
3 months-11.81%
6 months-13.53%
Current year-25.52%
1 week 5.28
Extreme 5.28
6.22
1 month 3.43
Extreme 3.43
6.22
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
44.98
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/6/26 Sell

Chief Executive Officer

-20,871 0.0339%
22/6/26 Sell

Chief Financial Officer

-4,089 0.0066%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-4.64%+7.08%+12.75%-36.53% 530M
+0.21%-1.34%+53.17%+60.65% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-0.62%+5.53%+409.46% 23.48B
+0.74%+2.20%-15.48%-14.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-1.15%+30.12%-32.02% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
-0.70%+0.36%+27.07%+183.04% 14.06B
Average +0.71%+0.40%+39.12%+159.69% 23.41B
Weighted average by Cap. +1.69%-0.71%+41.72%+140.73%

Financials

2026 *2027 *
Net sales 102M 89.29M 82.54M 75.91M 143M 9.82B 146M 987M 387M 4.81B 383M 374M 16.56B 178M 156M 144M 133M 251M 17.2B 255M 1.73B 677M 8.41B 670M 655M 28.99B
Net income -166M -145M -134M -123M -233M -15.96B -236M -1.6B -629M -7.81B -622M -608M -26.91B -142M -125M -115M -106M -200M -13.7B -203M -1.38B -540M -6.7B -533M -522M -23.09B
Net Debt -165M -145M -134M -123M -232M -15.91B -236M -1.6B -627M -7.79B -620M -606M -26.82B -210M -184M -170M -156M -295M -20.21B -299M -2.03B -796M -9.89B -787M -770M -34.07B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
21/07/26 USD 5.750 -4.64% 2,527,150
17/07/26 USD 6.030 +4.51% 3,562,397
16/07/26 USD 5.770 +0.70% 1,985,572
15/07/26 USD 5.730 +2.87% 2,083,595
14/07/26 USD 5.570 +3.72% 3,004,355
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.030USD
Average target price
15.00USD
Spread / Average Target
+148.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock